Acta Cell Biologica

In collaboration with Payame Noor University and Iranian Biology Society

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Paper Preparation Guide

Paper Template

Journal Forms

Guide of Abbreviations and Units

Word Count Policy

In silico evaluation of microRNAs in kidney renal clear cell ‎carcinoma and drugs effects in increasing apoptosis by docking

Document Type : Original Article

Authors

1 ‎Pediatric Health Research ‎Center, Tabriz University of ‎Medical Sciences, Tabriz, Iran‎

2 Department of Biology, Payame ‎Noor University (PNU), Tehran, ‎Iran‎

3 Tabriz University of Medical ‎Sciences, Tabriz, Iran‎

Abstract

Background: Kidney renal clear cell carcinoma account for 2-3% of the global cancer burden and has the highest death rate of any genitourinary malignancy. Apoptosis is one of the natural immune cycles that fight against cancers. MicroRNAs are small non-coding RNA molecules that can influence the function of proteins.
Methods: The functional cycles of four microRNAs (133b, 155, 185, 217) involved in kidney cancer apoptosis were identified. Then, the effects of 7 selected medications which is routinely used by specialist doctors to treat cancer (Cabozantinib, Doxorubicin, Everolimus, Nelarabine, Sorafenib, Sunitinib, and Temsirolimus) on the target proteins were evaluated with dynamic techniques and molecular docking. Docking with powerful servers was evaluated in terms of the possibility of occurrence. Finally, the chemical and medicinal properties (Admet), toxicity, mutagenicity, and site of action of the selected drugs were predicted in silico.
Results: The results indicated that drug Sunitinib had the best binding energy with 5 target proteins (VHL= -5, VEGF-A= -7.1, BACH1= -7.4, CUL4B= -5.1, JAK-2= -8 (kcal/mol)) and showed acceptable results in terms of molecular weight (398.5 Dalton), site of action (Mitochondria), and mutagenicity (0.5200 (negative)).
Conclusion: The identified evidence demonstrates the positive efficacy and effectiveness of sunitinib in various kidney carcinomas. Targeted therapies are steps towards the targeted increase of apoptosis and the control of cell proliferation and migration, which enable the correct treatment of renal clear cell carcinoma and the prescribing of drugs that cause the least secondary damage to patients.

Keywords

Main Subjects

References
Aghajanian, C., Filiaci, V., Dizon, D. S., Carlson, J. W., Powell, M. A., Secord, A. A., Tewari, K. S., Bender, D. P., O'Malley, D. M., & Stuckey, A. (2018). A phase II study of frontline paclitaxel/carboplatin/ bevacizumab, paclitaxel/carboplatin/ temsirolimus, or ixabepilone/carboplatin/ bevacizumab in advanced/recurrent endometrial cancer. Gynecologic oncology, 150(2), 274-281.
Apte, R. S., Chen, D. S., & Ferrara, N. (2019). VEGF in signaling and disease: beyond discovery and development. Cell, 176(6), 1248-1264.
Babiker, H. M., Karass, M., Recio-Boiles, A., Chandana, S. R., McBride, A., & Mahadevan, D. (2019). Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert opinion on investigational drugs, 28(7), 583-592.
Bates, D., & Eastman, A. (2017). Microtubule destabilising agents: far more than just antimitotic anticancer drugs. British journal of clinical pharmacology, 83(2), 255-268.
Bex, A., Jonasch, E., Kirkali, Z., Mejean, A., Mulders, P., Oudard, S., Patard, J.-J., Powles, T., Van Poppel, H., & Wood, C. G. (2010). Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. European urology, 58(6), 819-828.
Bosu, D. R., & Kipreos, E. T. (2008). Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell division, 3, 1-13.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 30(8), 1194-1220.
Cho, D. (2013). Novel targeting of Phoshatidylinositol-3 Kinase and Mammalian Target of Rapamycin (mTOR) in renal cell carcinoma. Cancer Journal (Sudbury, Mass.), 19(4), 311.
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology, 15(1), 49-63.
D'Agostino, D., Clematis, A., Quarati, A., Cesini, D., Chiappori, F., Milanesi, L., & Merelli, I. (2013). Cloud infrastructures for in silico drug discovery: economic and practical aspects. BioMed Research International, 2013.
Dias, F., Teixeira, A. L., Ferreira, M., Adem, B., Bastos, N., Vieira, J., Fernandes, M., Sequeira, M. I., Mauricio, J., & Lobo, F. (2017). Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma. Oncotarget, 8(61), 103315.
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., & Song, A. (2018). Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Molecular medicine reports, 17(5), 7163-7169.
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., & Kreissl, M. C. (2013). Cabozantinib in progressive medullary thyroid cancer. Journal of clinical oncology, 31(29), 3639.
Fu, Y., Zhao, Y., Liu, Y., Zhu, Y., Chi, J., Hu, J., Zhang, X., & Yin, X. (2012). Adenovirus-mediated tissue factor pathway inhibitor gene transfer induces apoptosis by blocking the phosphorylation of JAK-2/STAT-3 pathway in vascular smooth muscle cells. Cellular Signalling, 24(10), 1909-1917.
Gandhi, V., Keating, M. J., Bate, G., & Kirkpatrick, P. (2006). Nelarabine. Nature reviews Drug discovery, 5(1), 17-19.
Gaur, V., Wyatt, H. D., Komorowska, W., Szczepanowski, R. H., de Sanctis, D., Gorecka, K. M., West, S. C., & Nowotny, M. (2015). Structural and mechanistic analysis of the Slx1-Slx4 endonuclease. Cell reports, 10(9), 1467-1476.
Gossage, L., Eisen, T., & Maher, E. R. (2015). VHL, the story of a tumour suppressor gene. Nature Reviews Cancer, 15(1), 55-64.
Hamerlik, P., Lathia, J. D., Rasmussen, R., Wu, Q., Bartkova, J., Lee, M., Moudry, P., Bartek Jr, J., Fischer, W., & Lukas, J. (2012). Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. Journal of experimental medicine, 209(3), 507-520.
Hastie, T., Tibshirani, R., Friedman, J. H., & Friedman, J. H. (2009). The elements of statistical learning: data mining, inference, and prediction (Vol. 2). Springer.
Hosseini, M., Roshangar, L., Raeisi, S., Ghahremanzadeh, K., Negargar, S., Tarmahi, V., Hosseini, V., Raeisi, M., Rahimi, E., & Ebadi, Z. (2021). The therapeutic applications of exosomes in different types of diseases: A review. Current molecular medicine,21(2),87-95.
Ito, H., Ichiyanagi, O., Naito, S., Bilim, V. N., Tomita, Y., Kato, T., Nagaoka, A., & Tsuchiya, N. (2016). GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC cancer, 16(1), 1-12.
Kapetanovic, I. (2008). Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chemico-biological interactions, 171(2), 165-176.
Karthikeyan, C., Solomon, V. R., Lee, H., & Trivedi, P. (2013). Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach. Biomedicine & Preventive Nutrition, 3(4), 325-330.
Keating, G. M. (2017). Sorafenib: a review in hepatocellular carcinoma. Targeted oncology, 12, 243-253.
Kim, E.-A., Kim, S.-W., Nam, J., Sung, E.-G., Song, I.-H., Kim, J.-Y., Kwon, T. K., & Lee, T.-J. (2016). Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget, 7(22), 31832.
Kumamoto, T., Goto, H., Ogawa, C., Hori, T., Deguchi, T., Araki, T., Saito, A. M., Manabe, A., Horibe, K., & Toyoda, H. (2020). FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: A report from Japan Children’s Cancer Group. International Journal of Hematology, 112, 720-724.
Lafuente-Gracia, L., Borgiani, E., Nasello, G., & Geris, L. (2021). Towards in silico Models of the Inflammatory Response in Bone Fracture Healing. Frontiers in Bioengineering and Biotechnology, 9, 703725.
Lee, J., Yesilkanal, A. E., Wynne, J. P., Frankenberger, C., Liu, J., Yan, J., Elbaz, M., Rabe, D. C., Rustandy, F. D., & Tiwari, P. (2019). Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature, 568(7751), 254-258.
Li, F., Wang, Y., Chen, W.-l., Wang, D.-d., Zhou, Y.-j., You, B.-g., Liu, Y., Qu, C.-x., Chen, M.-t., & Zhang, X.-n. (2019). Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment. Theranostics, 9(20), 5886.
Lin, Z., Niu, Y., Wan, A., Chen, D., Liang, H., Chen, X., Sun, L., Zhan, S., Chen, L., & Cheng, C. (2020). RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO 3‐mediated autophagy. The EMBO journal, 39(12), e103181.
Ljungberg, B., Campbell, S. C., Cho, H. Y., Jacqmin, D., Lee, J. E., Weikert, S., & Kiemeney, L. A. (2011). The epidemiology of renal cell carcinoma. European urology, 60(4), 615-621.
Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. Archives of pharmacal research, 38(9), 1686-1701.
Man, S. M., & Kanneganti, T.-D. (2016). Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nature Reviews Immunology, 16(1), 7-21.
Maroto, P., Porta, C., Capdevila, J., Apolo, A. B., Viteri, S., Rodriguez-Antona, C., Martin, L., & Castellano, D. (2022). Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology, 14, 17588359221107112.
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., & Allen, A. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences, 105(30), 10513-10518.
Qi, X., Yang, M., Ma, L., Sauer, M., Avella, D., Kaifi, J. T., Bryan, J., Cheng, K., Staveley-O’Carroll, K. F., & Kimchi, E. T. (2020). Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. Journal for immunotherapy of cancer, 8(2).
Rai, A., Kumar, U., Raj, V., Singh, A. K., Kumar, P., Keshari, A. K., Kumar, D., Maity, B., De, A., & Samanta, A. (2018). Novel 1, 4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer. Pharmacological Research,132,188-203.
Roulin, D., Waselle, L., Dormond-Meuwly, A., Dufour, M., Demartines, N., & Dormond, O. (2011). Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Molecular cancer, 10, 1-12.
Schöler, N., Langer, C., Döhner, H., Buske, C., & Kuchenbauer, F. (2010). Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Experimental hematology,38(12),1126-1130.
Song, C. M., Lim, S. J., & Tong, J. C. (2009). Recent advances in computer-aided drug design. Briefings in bioinformatics, 10(5), 579-591.
Sonnenschein, C., & Soto, A. M. (2008). Theories of carcinogenesis: an emerging perspective. Seminars in cancer biology,
Spirina, L. V., Usynin, E. A., Yurmazov, Z. A., Slonimskaya, E. M., & Kondakova, I. V. (2017). Effect of targeted therapy with pazopanib on expression levels of transcription, growth factors and components of AKT/m-TOR signaling pathway in patients with renal cell carcinoma. Asian Pacific Journal of Cancer Prevention: APJCP, 18(11), 2977.
Tang, H., Liu, W., & Huang, K. (2022). Stereotactic ablative radiotherapy for inoperable T1‐2N0M0 small‐cell lung cancer. Thoracic Cancer, 13(7), 1100-1101.
Wang, X., Liu, J., Jiang, L., Wei, X., Niu, C., Wang, R., Zhang, J., Meng, D., & Yao, K. (2016). Bach1 induces endothelial cell apoptosis and cell-cycle arrest through ROS generation. Oxidative medicine and cellular longevity, 2016.
Wang, Y., Pan, X., Li, Y., Wang, R., Yang, Y., Jiang, B., Sun, G., Shao, C., Wang, M., & Gong, Y. (2021). CUL4B renders breast cancer cells tamoxifen‐resistant via miR‐32‐5p/ER‐α36 axis. The Journal of Pathology, 254(2), 185-198.
Witten, D. M., & Tibshirani, R. (2008). Testing significance of features by lassoed principal components. The annals of applied statistics, 2(3), 986.
Xu, F., Xia, T., Xu, Q.-T., Zhang, X., Huang, Y.-Z., Sun, X., Shi, L., Zhou, X.-J., Wei, J.-F., & Ding, Q. (2022). RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression. International Journal of Biological Sciences, 18(4), 1724.
Xue, D., Wang, H., Chen, Y., Shen, D., Lu, J., Wang, M., Zebibula, A., Xu, L., Wu, H., & Li, G. (2019). Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Molecular cancer, 18(1), 1-13. 
Acta Cell Biologica
Volume 1, Issue 1
March 2025
Pages 11-16
Files
Share
How to cite
Statistics